Related references
Note: Only part of the references are listed.Long-term safety, tolerability, and efficacy of fremanezumab in migraine A randomized study
Peter J. Goadsby et al.
NEUROLOGY (2020)
Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials
Rashmi B. Halker Singh et al.
CEPHALALGIA (2019)
Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine
Machaon Bonafede et al.
CEPHALALGIA (2019)
Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
Kaname Ueda et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Orit Cohen-Barak et al.
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Fremanezumab for preventive treatment of migraine Functional status on headache-free days
Juliana VanderPluym et al.
NEUROLOGY (2018)
Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States
J. Michael Woolley et al.
HEADACHE (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability
Richard B. Lipton et al.
HEADACHE (2016)
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
Marcelo E. Bigal et al.
NEUROLOGY (2016)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study
Sun-Young Kim et al.
JOURNAL OF HEADACHE AND PAIN (2014)
The International Classification of Headache Disorders, 3rd edition (beta version)
Andre Bes et al.
CEPHALALGIA (2013)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
Peer Tfelt-Hansen et al.
CEPHALALGIA (2012)
Defining the Differences Between Episodic Migraine and Chronic Migraine
Zaza Katsarava et al.
CURRENT PAIN AND HEADACHE REPORTS (2012)
Feasibility and validation of a computer-automated Columbia-Suicide severity rating scale using interactive voice response technology
James C. Mundt et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2010)
Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability
WF Stewart et al.
NEUROLOGY (2001)
Share Paper
